Cargando…

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma

Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. However, the overall response rate to immune checkpoint inhibitor therapy for many cancers is only between 20 and 40%, and even less for colorectal cancer (CRC) patients. Thus, there is an urgent need to develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Yuyin, Peng, Yujia, Zhao, Shengyan, Mou, Jun, Zeng, Lishi, Jiang, Xiaohua, Yang, Chengli, Huang, Cheng, Li, Yuyan, Lu, Yin, Wu, Mengdan, Yang, Yanfang, Kong, Ting, Lai, Qinhuai, Wu, Yangping, Yao, Yuqin, Wang, Yuxi, Gou, Lantu, Yang, Jinliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298272/ https://www.ncbi.nlm.nih.gov/pubmed/34307367 http://dx.doi.org/10.3389/fcell.2021.689727

Ejemplares similares

Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma
por: Tao, Yiran, et al.
Publicado: (2019)

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017)

Effective antitumor activity of 5T4‐specific CAR‐T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo
por: Guo, Cuiyu, et al.
Publicado: (2020)

Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models
por: Yu, Lin, et al.
Publicado: (2017)

Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling
por: Chen, Xiangzheng, et al.
Publicado: (2016)

56. Foretinib Enhances Myelination of Neurons in Vitro
por: Mirmoeini, Kaveh, et al.
Publicado: (2023)

Establishment and characterization of intraperitoneal xenograft models by co-injection of human tumor cells and extracellular matrix gel
por: YAO, YUQIN, et al.
Publicado: (2015)

Foretinib mitigates cutaneous nerve fiber loss in experimental diabetic neuropathy
por: Daeschler, Simeon C., et al.
Publicado: (2022)

Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met
por: Chen, Guang-Zong, et al.
Publicado: (2017)

FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma
por: Zhang, Guangbing, et al.
Publicado: (2022)

Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer
por: Kogata, Yuhei, et al.
Publicado: (2018)

Antibody–drug conjugates: Recent advances in payloads
por: Wang, Zhijia, et al.
Publicado: (2023)

Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
por: Dratkiewicz, Ewelina, et al.
Publicado: (2018)

Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
por: Lu, Ying, et al.
Publicado: (2019)

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
por: Hassan, Md. Sazzad, et al.
Publicado: (2019)

Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling
por: Sohn, Sung-Hwa, et al.
Publicado: (2020)

UPLC–MS/MS assay for quantification of an inhibitor of kinases (Foretinib) in plasma: Application to a pharmacokinetic study in rats
por: Ezzeldin, Essam, et al.
Publicado: (2020)

Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation
por: Alanazi, Mohammed M., et al.
Publicado: (2019)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
por: Simiczyjew, Aleksandra, et al.
Publicado: (2018)

Radiation-induced FAP + fibroblasts are involved in keloid recurrence after radiotherapy
por: Gao, Yan, et al.
Publicado: (2022)

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Seiwert, Tanguy, et al.
Publicado: (2012)

Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling
por: Chen, Hsiu-Mei, et al.
Publicado: (2015)

Transcriptomic Analysis Identified ARHGAP Family as a Novel Biomarker Associated With Tumor-Promoting Immune Infiltration and Nanomechanical Characteristics in Bladder Cancer
por: Yang, Chen, et al.
Publicado: (2021)

Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models
por: Grojean, Meghan, et al.
Publicado: (2021)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Mechanism of microtubule stabilization by taccalonolide AJ
por: Wang, Yuxi, et al.
Publicado: (2017)

HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma
por: Peng, Jinxia, et al.
Publicado: (2020)

Polymorphisms in CISH Gene Are Associated with Persistent Hepatitis B Virus Infection in Han Chinese Population
por: Hu, Zhangyong, et al.
Publicado: (2014)

EpCAM as a Novel Biomarker for Survivals in Prostate Cancer Patients
por: Liao, Yang, et al.
Publicado: (2022)

New hope for tumor immunotherapy: the macrophage-related “do not eat me” signaling pathway
por: Deng, Han, et al.
Publicado: (2023)

The Regulatory NOD-Like Receptor NLRC5 Promotes Ganglion Cell Death in Ischemic Retinopathy by Inducing Microglial Pyroptosis
por: Deng, Yang, et al.
Publicado: (2021)

Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
por: Ji, Xiwei, et al.
Publicado: (2023)

Malignant ascites-derived exosomes promote proliferation and induce carcinoma-associated fibroblasts transition in peritoneal mesothelial cells
por: Wei, Mingtian, et al.
Publicado: (2017)

PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review
por: Wang, Jen-Chin, et al.
Publicado: (2022)

Non-coding RNA Regulated Cross-Talk Between Mitochondria and Other Cellular Compartments
por: Huang, Jinliang, et al.
Publicado: (2021)

Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy
por: Xiao, Chu, et al.
Publicado: (2022)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
por: Shah, Manish A., et al.
Publicado: (2021)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
por: Shah, Manish A., et al.
Publicado: (2022)

β-Arrestin1 Mediates the Endocytosis and Functions of Macrophage Migration Inhibitory Factor
por: Xie, Lishi, et al.
Publicado: (2011)

CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas
por: Li, Depei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d0etleq0r0q6pi792vd7c7vmjq